Inactivated poliomyelitis vaccine (IPOL)
Sponsors
CanSino Biologics Inc., Serum Institute of India Pvt. Ltd.
Conditions
Polio ImmunityPoliomyelitis
Phase 1
A Study to Evaluate the Safety and Immunogenicity of Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell) in Healthy Adults
CompletedNCT06101173
Start: 2024-01-15End: 2024-09-11Updated: 2024-12-04
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Not yet recruitingNCT07688369
Start: 2026-07-01End: 2027-03-01Target: 36Updated: 2026-07-10